A Comprehensive Monograph on Pyronaridine: From Chemical Structure to Global Clinical Application

I. Introduction and Drug Profile

1.1 Executive Summary

Pyronaridine is a small molecule, benzonaphthyridine derivative that functions as a potent antimalarial agent.[1] Its primary therapeutic indication is the treatment of acute, uncomplicated malaria caused by the two most significant human malaria parasites,

Plasmodium falciparum and Plasmodium vivax.[1] As a blood schizonticide, Pyronaridine exerts its principal mechanism of action by interfering with the parasite's critical heme detoxification pathway, specifically through the inhibition of hemozoin biocrystallization within the parasite's digestive vacuole.[2] Although first developed in the 1970s as a monotherapy, its contemporary clinical relevance is defined by its co-formulation with the artemisinin derivative artesunate. This fixed-dose artemisinin-based combination therapy (ACT), marketed globally as Pyramax®, leverages the synergistic action of a fast-acting artemisinin component with the long-acting, mechanistically distinct Pyronaridine.[6] This combination represents a critical tool in the global public health strategy to manage and overcome the challenge of multidrug-resistant malaria, offering a valuable alternative to older ACTs facing declining efficacy.[7]

1.2 Chemical and Physical Characterization

The precise identification and characterization of a pharmaceutical agent are fundamental to its development, manufacturing, and clinical application. Pyronaridine's chemical and physical properties define its formulation, stability, and biological behavior.

Identifiers and Nomenclature

Pyronaridine is known by several chemical names and is cataloged in numerous international databases, ensuring its unambiguous identification by researchers, clinicians, and regulatory bodies.

• Generic Name: Pyronaridine.[1]
• DrugBank ID: DB12975.[1]
• CAS Number: The free base form of the molecule is assigned CAS number 74847-35-1.[9] The commercially formulated tetraphosphate salt is identified by CAS number 76748-86-2.[10]
• Synonyms: It has been referred to historically and in literature as Malaridine and Benzonaphthyridine 7351.[10]
• IUPAC Name: The systematic chemical name for the compound is 4-[(7-chloro-2-methoxybenzo[b]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol.[9]

Chemical Structure and Formula

Pyronaridine is a complex heterocyclic compound, structurally classified as a benzonaphthyridine derivative and a member of the broader 4-aminoquinoline class of antimalarials.[1] It is also chemically described as a Mannich base, a class of organic compounds formed via the aminoalkylation of an acidic proton located on an active hydrogen compound.[6]

• Chemical Formula: The molecular formula for the free base is C29​H32​ClN5​O2​.[1]
• Molecular Weight: The average molecular weight is 518.06 g/mol, with a monoisotopic mass of 517.2245 g/mol.[1]

Physicochemical Properties

The physical properties of Pyronaridine, particularly the differences between its free base and salt forms, dictate its formulation characteristics and pharmacokinetic behavior.

• Formulations: In its clinical application, Pyronaridine is available exclusively as the tetraphosphate salt. This salt is co-formulated with artesunate in a fixed 3:1 ratio by weight to produce the final medicinal product, Pyramax®.[2] This combination is available in two main dosage forms: film-coated tablets containing 180 mg of pyronaridine tetraphosphate and 60 mg of artesunate, and granules for oral suspension, with each sachet containing 60 mg of pyronaridine tetraphosphate and 20 mg of artesunate.[3]
• Appearance: The tetraphosphate salt is a hygroscopic, yellow crystalline powder or needles, characterized by a bitter taste.[2]
• Solubility: The solubility profile differs significantly between the free base and the salt. The free base is practically insoluble in water but demonstrates solubility in organic solvents such as dimethyl sulfoxide (DMSO) at 6 mg/mL and ethanol at 4 mg/mL.[17] In contrast, the tetraphosphate salt is sparingly soluble in water (approximately 1.46% w/v) and shows a higher solubility of about 10 mg/mL in phosphate-buffered saline (PBS) at a physiological pH of 7.2.[2]
• Melting Point: Reports on the melting point vary, likely due to differences in the specific form (free base vs. salt) and experimental conditions. Some sources report a melting point of 233-236°C with decomposition for the tetraphosphate salt.[16] Another source indicates a decomposition point above 202°C.[18] Other references list the value as undetermined, underscoring the compound's thermal lability.[21]
• pKa: As a polybasic compound, Pyronaridine possesses four ionization constant (pKa) values. Experimentally measured values by titration are 7.08, 7.39, 9.88, and 10.30, reflecting its multiple protonatable nitrogen atoms.[2]

Table 1: Chemical and Physical Properties of Pyronaridine

Property	Free Base	Tetraphosphate Salt
IUPAC Name	4-[(7-chloro-2-methoxybenzo[b]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol	Not Applicable
CAS Number	74847-35-1	76748-86-2
Molecular Formula	C29​H32​ClN5​O2​	C29​H32​ClN5​O2​⋅4(H3​PO4​)
Molecular Weight	518.06 g/mol	910.03 g/mol
Appearance	Not specified	Hygroscopic, yellow powder/needles
Solubility in Water	Insoluble	Sparingly soluble (1.46% w/v)
Solubility in DMSO	6 mg/mL	Not specified
Solubility in Ethanol	4 mg/mL	Not specified
Melting Point	Not specified	>202-236°C (with decomposition)

1.3 Historical Development and Evolution

The trajectory of Pyronaridine's development mirrors the broader evolution of global antimalarial strategy over the past half-century. Its journey from a national monotherapy to a globally endorsed combination therapy partner illustrates a critical paradigm shift in infectious disease pharmacology, driven by the relentless pressure of drug resistance.

Pyronaridine was first synthesized in the 1970s at the Institute of Chinese Materia Medica in response to the widespread emergence of chloroquine-resistant Plasmodium falciparum.[14] Following preclinical and clinical evaluation, it was introduced for clinical use in China during the 1980s as a monotherapy under the trade name Malaridine.[6] Early studies confirmed its high efficacy against chloroquine-resistant strains and demonstrated a more favorable toxicity profile compared to chloroquine.[14]

Despite its initial success, the long-term viability of Pyronaridine as a monotherapy was inherently limited. The history of antimalarial chemotherapy has repeatedly shown that deploying single agents with long elimination half-lives inevitably selects for resistant parasites, a lesson reinforced by the later emergence of resistance to artemisinin monotherapies.[23]

The global landscape shifted in the early 2000s when the World Health Organization (WHO) issued a strong recommendation for the universal adoption of artemisinin-based combination therapies (ACTs) to combat the growing threat of multidrug resistance.[25] This strategic pivot created a new role for drugs like Pyronaridine. Its distinct mechanism of action and, crucially, its long pharmacokinetic half-life made it an ideal candidate to serve as a long-acting "partner" drug. In an ACT, the fast-acting artemisinin derivative rapidly reduces the parasite biomass, while the longer-acting partner persists to eliminate the remaining parasites, thereby preventing recrudescence and protecting the artemisinin component from resistance development.[2]

Recognizing this potential, a product development partnership was formed in 2002 between Shin Poong Pharmaceutical Co., Ltd. of South Korea and the Medicines for Malaria Venture (MMV), a non-profit organization dedicated to discovering, developing, and delivering new antimalarial drugs.[5] This collaboration was tasked with developing a co-formulated, fixed-dose combination (FDC) of Pyronaridine and artesunate. The FDC approach was critical for ensuring adherence and preventing the use of either component as a monotherapy, a key lesson from past failures in malaria control.[26] This partnership model, uniting pharmaceutical industry expertise with non-profit, public-health-focused oversight, proved essential for navigating the complex and costly path of clinical development and international regulatory approval for a disease that primarily affects low-income countries. The resulting product, Pyramax®, would ultimately become a key addition to the global antimalarial armamentarium.

II. Preclinical and Clinical Pharmacology

The therapeutic utility of Pyronaridine is rooted in its specific molecular interactions with the malaria parasite and its distinct pharmacokinetic behavior within the human body. A comprehensive understanding of its pharmacology is essential for its rational clinical use, for anticipating potential adverse effects, and for positioning it within the broader landscape of antimalarial agents.

2.1 Primary Mechanism of Antimalarial Action: Hemozoin Inhibition

Pyronaridine is a potent blood schizonticide, meaning it is active against the asexual, intra-erythrocytic stages of the Plasmodium parasite's lifecycle, which are responsible for the clinical symptoms of malaria.[2] Its primary mechanism of action is the disruption of the parasite’s heme detoxification system, a pathway shared by other quinoline-type antimalarials like chloroquine but targeted by Pyronaridine with superior potency.[2]

The process begins as the parasite, residing within a host red blood cell, ingests large quantities of hemoglobin from the host cell's cytoplasm into its acidic digestive vacuole. The digestion of hemoglobin provides essential amino acids for parasite growth but also releases vast amounts of heme (ferriprotoporphyrin IX), which is highly toxic to the parasite due to its ability to generate reactive oxygen species and disrupt membrane integrity.[2] To neutralize this threat, the parasite has evolved a unique detoxification process: it polymerizes the soluble, toxic heme into an insoluble, chemically inert, crystalline pigment known as hemozoin, or "malaria pigment".[2]

Pyronaridine directly interferes with this vital detoxification process. As a weak base, it is thought to accumulate in the acidic digestive vacuole of the parasite. There, it binds with high affinity to heme (specifically, haematin) to form a stable drug-haematin complex, which has been shown to have a stoichiometric ratio of 1:2 (one Pyronaridine molecule to two heme molecules).[2] The formation of this complex physically obstructs the heme molecules from being incorporated into the growing hemozoin crystal lattice, thereby inhibiting the polymerization process.[2]

The consequence of this inhibition is the accumulation of toxic, free heme within the digestive vacuole and parasite cytoplasm. This buildup leads to overwhelming oxidative stress, lipid peroxidation, membrane damage, and ultimately, parasite death.[2]

A key distinction between Pyronaridine and its predecessor, chloroquine, lies in its potency and the specific stage of hemozoin formation it targets. While both drugs inhibit the process, studies have shown that Pyronaridine is approximately tenfold more potent than chloroquine at inhibiting the initial nucleation of beta-hematin (the synthetic equivalent of hemozoin) crystals. Chloroquine, by contrast, is more active at inhibiting the subsequent extension or growth of these crystals.[30] This enhanced activity against the nucleation step may explain Pyronaridine's superior clinical activity against early-stage parasites (ring stages) compared to chloroquine, providing a broader window of parasiticidal action within each erythrocytic cycle.[30]

2.2 Secondary Pharmacodynamic Effects

In addition to its well-established role as a hemozoin inhibitor, preclinical evidence suggests that Pyronaridine may possess other pharmacodynamic activities. In vitro studies have demonstrated that Pyronaridine can intercalate into double-stranded DNA and function as an inhibitor of DNA topoisomerase II (Topo2) enzymes.[2] Topoisomerases are essential enzymes that manage the topological state of DNA during replication, transcription, and repair. Their inhibition can lead to DNA strand breaks and cell death.

This secondary mechanism could theoretically contribute to its parasiticidal effect by disrupting essential nucleic acid metabolism within the parasite.[4] Furthermore, this activity is believed to underpin the broader biological effects observed in preclinical models, such as its potential as an anticancer agent.[10] However, the precise contribution of Topo2 inhibition to Pyronaridine's

antimalarial efficacy in a clinical context remains a subject of ongoing investigation. Some experimental studies have yielded conflicting results, and the overwhelming consensus is that its potent and rapid parasiticidal action is primarily attributable to the disruption of heme detoxification.[2]

2.3 Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of Pyronaridine is a defining feature that has profoundly influenced its clinical development, therapeutic rationale, and safety considerations. Its behavior in the body—characterized by rapid absorption, extensive distribution into its target compartment, and a very long elimination half-life—is a double-edged sword that provides significant therapeutic advantages while also necessitating careful safety evaluation.

Absorption

Following oral administration, Pyronaridine is absorbed relatively rapidly from the gastrointestinal tract.[2] The time to reach peak plasma concentration (

Tmax​) is generally observed between 2 and 8 hours after dosing.[32] Studies evaluating food effects have shown that co-administration with a high-fat meal results in a modest increase in systemic exposure (approximately 20-34%). However, this effect was not deemed clinically significant, granting the convenience of administration without regard to meals.[32]

Distribution

The distribution of Pyronaridine is one of its most critical pharmacokinetic attributes. It exhibits a very large apparent volume of distribution (Vd​), indicating extensive distribution into tissues outside of the plasma compartment.[2] Population pharmacokinetic modeling in pediatric patients estimated the central volume of distribution (

V2​/F) to be 2,230 liters and the peripheral volume (V3​/F) to be 3,230 liters, values that far exceed total body water, confirming extensive tissue sequestration.[34]

Most importantly, Pyronaridine demonstrates a strong tendency to accumulate in erythrocytes (red blood cells), the site of malarial infection. This leads to a high blood-to-plasma concentration ratio, which has been reported to range from 1.6 to as high as 17.8.[6] This preferential partitioning ensures that high concentrations of the drug are delivered directly to its parasitic target, a feature believed to be crucial for its potent pharmacological activity.[2]

Metabolism

Pyronaridine undergoes extensive hepatic metabolism prior to elimination. A human mass balance study using radiolabeled drug was instrumental in elucidating its metabolic fate, identifying a total of nine primary and four secondary metabolites in blood, urine, and feces.[36]

In vitro studies using human liver microsomes and recombinant enzymes have implicated several Cytochrome P450 (CYP) isoenzymes in its biotransformation, principally CYP1A2, CYP2D6, and CYP3A4.[36] The identified metabolic pathways are varied and include N-dearylation, oxidation, and de-methylation.[36]

Elimination

The elimination of Pyronaridine and its metabolites is a slow, prolonged process that occurs via both renal and fecal routes. The human mass balance study found that, on average, 23.7% of the administered dose was recovered in urine and 47.8% in feces over the study period, for a total recovery of 71.5%.[36]

The most striking feature of its elimination is its exceptionally long terminal half-life (t1/2​). The half-life of the parent Pyronaridine compound in adults has been reported to be in the range of 5 to 18 days.[32] Even more significant is the half-life of total drug-related radioactivity, which includes all metabolites. This has a mean value of 33.5 days, substantially longer than that of the parent drug.[36] This discrepancy indicates the formation of one or more long-lasting metabolites that persist in the body for an extended period after the parent drug has been cleared.

This distinct pharmacokinetic profile was a central consideration throughout the drug's development. On one hand, the long half-life and high erythrocyte accumulation are ideal properties for an ACT partner drug. This ensures that sustained parasiticidal concentrations are maintained long after the short-acting artesunate has been eliminated, which is critical for clearing residual parasites, preventing recrudescence, and providing a period of post-treatment prophylaxis against new infections.[2] On the other hand, this same profile raised significant safety questions, particularly regarding the potential for drug accumulation and cumulative toxicity upon re-treatment of subsequent malaria episodes, a common occurrence in endemic regions.[37] This concern directly shaped the design of the pivotal clinical trial program. For instance, the WANECAM trial included a specific, planned substudy to prospectively gather robust safety and efficacy data on patients receiving multiple courses of the drug.[38] The successful demonstration that re-treatment did not increase safety risks was a landmark finding, essential for securing a broader regulatory label from agencies like the European Medicines Agency (EMA) and transforming the drug from a niche, single-use therapy into a widely applicable first-line treatment.[37] Thus, the pharmacokinetic properties of Pyronaridine are not merely a set of parameters but are the central narrative that explains its therapeutic rationale, its primary safety concern, its clinical trial design, and its ultimate regulatory success.

Table 2: Summary of Key Pharmacokinetic Parameters for Pyronaridine

Parameter	Value / Description	Source(s)
Time to Peak Concentration (Tmax​)	2 - 8 hours	32
Apparent Clearance (CL/F)	377 L/day (in pediatric patients)	34
Apparent Volume of Distribution (Vd​/F)	Central (V2/F): 2,230 L; Peripheral (V3/F): 3,230 L (in pediatric patients)	34
Blood-to-Plasma Ratio	High; ranges from 1.6 to 17.8	6
Terminal Half-life (t1/2​)	Parent Compound: 5 - 18 days	32
	Total Radioactivity (Parent + Metabolites): 33.5 days	36
Bioavailability	Food effect not clinically significant	32
Primary Metabolic Pathways	N-dearylation, oxidation, de-methylation via CYP1A2, CYP2D6, CYP3A4	36
Route of Excretion	Fecal (~48%) and Urinary (~24%)	36

III. Clinical Evidence and Therapeutic Efficacy

The clinical value of Pyronaridine-artesunate has been established through a comprehensive program of Phase II and Phase III clinical trials conducted across diverse epidemiological settings in Africa and Asia. This body of evidence demonstrates its high efficacy against the major human malaria species and in key patient populations, while also providing valuable insights into the evolving challenge of antimalarial drug resistance.

3.1 Efficacy in Plasmodium falciparum Malaria

The performance of Pyronaridine-artesunate against P. falciparum, the most virulent malaria parasite, has been rigorously evaluated in large-scale, comparative clinical trials.

Pivotal Phase III Trials

A landmark Phase III, open-label, non-inferiority trial, published in the New England Journal of Medicine, provided pivotal evidence for the drug's efficacy.[40] The study enrolled 1,271 patients with uncomplicated

P. falciparum malaria across 10 sites in Africa and Southeast Asia, comparing a three-day course of Pyronaridine-artesunate (PA) with the standard-of-care combination of mefloquine plus artesunate (MQ+AS).[40] The primary efficacy endpoint was the polymerase chain reaction (PCR)-corrected adequate clinical and parasitological response (ACPR) at Day 28 in the per-protocol population. The results demonstrated non-inferiority, with an ACPR of 99.2% for the PA group compared to 97.8% for the MQ+AS group.[40]

However, this trial also yielded a critical finding that served as an early warning of shifting resistance patterns. In the study cohort from Cambodia, a known hotspot for antimalarial resistance, the rate of recrudescence (treatment failure) by Day 42 was significantly higher in the PA group (10.2%) compared to the MQ+AS group (0%). This was accompanied by markedly prolonged parasite clearance times in the region.[40] This outcome was not a failure of Pyronaridine itself, but rather a clinical manifestation of emerging resistance to its partner drug, artesunate. When the fast-acting artemisinin component is compromised and clears parasites more slowly, it places greater pressure on the long-acting partner drug, increasing the likelihood of failure. This finding from the PA trial was a powerful real-time indicator of the spread of artemisinin resistance (later linked to Kelch13 gene mutations) in the Greater Mekong Subregion, a trend that has since been extensively confirmed by molecular and clinical surveillance.[24]

Regional Efficacy and Meta-Analyses

Outside of regions with high-grade artemisinin resistance, clinical trials have consistently reported excellent efficacy for PA.

• In Myanmar, studies conducted between 2017 and 2019 found a Day 42 PCR-corrected ACPR of over 96% against P. falciparum.[42]
• Even within Cambodia, studies in eastern provinces where resistance was less established at the time reported Day 42 ACPR rates of over 96% and 98%.[23]
• In West Africa, the large WANECAM trial demonstrated a Day 28 PCR-corrected ACPR of over 95%.[38]
• A comprehensive Cochrane Review, which synthesized data from five randomized controlled trials involving over 5,700 participants, corroborated these findings. The meta-analysis concluded that PA achieves a PCR-adjusted treatment failure rate of less than 5% at both Day 28 and Day 42, and that its efficacy is at least as good as, and may be better than, other WHO-recommended ACTs, including artemether-lumefantrine and artesunate-amodiaquine.[43]

Table 3: Comparative Efficacy of Pyronaridine-Artesunate vs. Standard ACTs in Pivotal Phase III Trials for P. falciparum Malaria

Trial Reference / Identifier	Geographic Region	Comparator Drug	Population	Primary Endpoint (Day 28 PCR-Corrected ACPR)	Pyronaridine-Artesunate Efficacy (%, 95% CI)	Comparator Efficacy (%, 95% CI)
Tshefu et al., NEJM 2012 40	Africa & Asia	Mefloquine + Artesunate	Adults & Children (≥20kg)	Per-Protocol	99.2% (98.3 - 99.7)	97.8% (95.8 - 99.1)
WANECAM Substudy 38	West Africa	Artemether-Lumefantrine	Adults & Children (≥5kg)	Per-Protocol (all episodes)	>95%	>95%
Cochrane Review 2022 44	Africa & Asia	Artemether-Lumefantrine	Adults & Children	Meta-Analysis	May be superior (RR 0.59)	-
Cochrane Review 2022 44	Africa	Artesunate-Amodiaquine	Adults & Children	Meta-Analysis	May be superior (RR 0.55)	-
Note: The Tshefu et al. trial reported significantly higher recrudescence rates with Pyronaridine-Artesunate in the Cambodian cohort by Day 42, reflecting regional artemisinin resistance.

3.2 Efficacy in Plasmodium vivax Malaria

Pyronaridine-artesunate is notable for being one of the few ACTs that has been specifically registered and extensively evaluated for the treatment of blood-stage P. vivax malaria.[33] This is a significant advantage, as

P. vivax is the second most prevalent human malaria parasite and a major cause of morbidity, particularly in Asia and the Americas.

Clinical trial data have confirmed its high efficacy against this species.

• In a series of four single-arm studies conducted in Myanmar, the Day 28 ACPR for P. vivax was 100% at both northern and southern study sites, with 100% of patients achieving parasite clearance by Day 3.[42]
• A study in Vietnam evaluated PA for P. vivax treatment where patients also received a standard 14-day course of primaquine for radical cure. The Day 42 PCR-unadjusted ACPR was 96.0%, with rapid parasite and fever clearance times.[45]

It is essential to emphasize that PA, like all other ACTs, is only active against the blood stages of the parasite (it is a blood schizonticide). It has no activity against the dormant liver-stage forms of P. vivax, known as hypnozoites. Therefore, to achieve a radical cure and prevent future relapses from these liver stages, treatment with PA must be followed by a course of a hypnozoitocidal drug, such as primaquine or tafenoquine.[45]

3.3 Performance in Special Populations and Re-treatment

A key strength of the Pyronaridine-artesunate development program has been the deliberate inclusion and evaluation of the drug in critical and often-neglected patient populations.

Pediatrics

Recognizing that young children bear the highest burden of malaria mortality, a specific pediatric formulation was developed. The creation of taste-masked, water-dispersible granules (60 mg PA / 20 mg AS) for infants and children weighing between 5 kg and 20 kg was a major advance in pediatric antimalarial therapy.[3] This formulation overcomes the significant challenges of inaccurate dosing that arise from crushing or splitting adult tablets, a common and unsafe practice in many resource-limited settings.[47] Clinical trials in pediatric populations have confirmed that the granule formulation provides comparable exposure and has a similar high efficacy and safety profile to the tablet formulation used in older children and adults.[25]

Re-treatment in High-Transmission Areas

As previously discussed, the long half-life of Pyronaridine raised concerns about its safety upon repeated use. The Phase IIIb/IV WANECAM trial, conducted in high-transmission areas of West Africa, was designed to address this question directly. The trial followed patients for up to two years and re-treated subsequent episodes of uncomplicated malaria with the same initial therapy. A planned substudy analysis compared the safety and efficacy outcomes of the first treatment episode with those of subsequent re-treatments.[38] The results were reassuring: the incidence of adverse events, including the key safety signal of hepatotoxicity, was not increased upon re-treatment. Efficacy also remained high, with a PCR-corrected ACPR of over 95% at Day 28 for both first and subsequent treatment episodes.[38] This evidence was pivotal, as it supported the expansion of the drug's label to allow for repeated use, making it a viable treatment option for populations living in highly endemic areas.

Pregnancy

Pregnant women are a high-risk group for malaria, yet they are often excluded from clinical trials, leading to a dearth of safety and efficacy data for most antimalarials. Historically, PA was not recommended for use in pregnancy due to this lack of data.[48] To address this evidence gap, two major initiatives were launched: the PYRAPREG clinical trial, which evaluated PA in the second and third trimesters, and the Malaria in Mothers and Babies (MiMBa) pregnancy registry, which collected real-world safety data.[48] Interim results from these studies provided sufficient evidence of a favorable safety profile, leading the EMA to update the Pyramax product label in mid-2025 to reflect that it can be used during the second and third trimesters of pregnancy.[48] In line with general guidance for all artemisinin-based therapies, its use during the first trimester remains cautioned against and should only be considered if other suitable treatments are not available.[46] This label update represents a major step forward in expanding the limited treatment options available for pregnant women with malaria.

IV. Safety, Tolerability, and Risk Management

The safety profile of Pyronaridine-artesunate has been extensively characterized in a clinical development program involving over 3,500 patients.[33] While generally well-tolerated, it is associated with a specific safety signal related to liver function that requires careful clinical management. A thorough understanding of its adverse event profile, drug interaction potential, and contraindications is essential for its safe and effective use.

4.1 Adverse Event Profile

The overall profile of adverse events observed with Pyronaridine-artesunate is largely consistent with the symptoms of the underlying malaria infection and is comparable to that of other widely used ACTs.[8] The most frequently reported adverse drug reactions, occurring in 1% to 10% of patients in clinical trials, include [3]:

• Hematological: Eosinophilia (increase in eosinophil count), neutropenia (decrease in neutrophil count), anemia (low red blood cell count), and thrombocytosis (increased platelet count).
• Gastrointestinal: Vomiting and abdominal pain.
• Neurological: Headache.
• Cardiac: Bradycardia (slow heart rate).
• Biochemical: Transient elevations in liver aminotransferases (ALT and AST) and hypoglycemia.

Additionally, the tablet and granule formulations contain the azo dye colorants tartrazine (E102) and sunset yellow (E110).[46] These excipients are known to carry a risk of causing allergic or hypersensitivity reactions in susceptible individuals.[46] In light of this, the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended that the manufacturer evaluate alternative formulations that do not contain these organic colorants.[47]

4.2 Hepatotoxicity Assessment

The most distinct and clinically significant safety finding associated with Pyronaridine-artesunate is a risk of transient, asymptomatic elevations in hepatic transaminases, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST).[8] This signal prompted a thorough and systematic approach to risk characterization and management throughout the drug's development and post-marketing surveillance.

The pattern of these liver enzyme elevations is predictable. They are typically mild to moderate in severity, begin to appear early after treatment initiation, peak around Day 7, and subsequently resolve to baseline levels by Day 28 in the vast majority of cases.[38] A comprehensive Cochrane review systematically analyzed this risk and found that the incidence of biochemical liver enzyme elevations was approximately four times more frequent in patients receiving PA compared to those receiving other antimalarial treatments (Risk Ratio 4.17).[8]

While these biochemical changes are common, progression to severe drug-induced liver injury (DILI) is very rare. Cases meeting Hy's Law criteria—a prognostic indicator for severe DILI defined by concurrent elevation of aminotransferases and bilirubin—have been exceptionally infrequent, with only one possible case reported in the large WANECAM trial involving nearly 1,000 patients receiving a first treatment course.[38]

This detailed characterization of the hepatotoxicity risk allowed for a nuanced risk-benefit assessment by regulatory authorities. The conclusion was that for the vast majority of patients with uncomplicated malaria, the benefit of treatment with a highly effective ACT overwhelmingly outweighs the low risk of a transient, self-resolving, and asymptomatic elevation in liver enzymes. The risk was then proactively managed through specific labeling and contraindications. Pyramax is strictly contraindicated for use in patients with pre-existing severe liver disease (e.g., decompensated cirrhosis) or in those who present with clinical signs or symptoms of hepatic injury, such as jaundice.[3] This targeted approach effectively mitigates the risk in the highest-risk population while preserving access to a vital medicine for the broader patient population.

4.3 Significant Drug-Drug Interactions

Pyronaridine has the potential to interact with other medications through several mechanisms, which necessitates caution when co-administering certain drugs.

QTc Prolongation

Pyronaridine may increase the risk of QTc interval prolongation, an electrocardiogram (ECG) finding that can predispose individuals to life-threatening cardiac arrhythmias like Torsades de Pointes. This risk is additive when Pyronaridine is combined with other drugs known to prolong the QTc interval.[1] Clinically relevant classes of interacting drugs include:

• Other Antimalarials: Artemether, Lumefantrine, Mefloquine.
• Antipsychotics/Neuroleptics: Phenothiazines such as Perphenazine, Promethazine, and Fluphenazine.
• Other Agents: Certain antiarrhythmics, macrolide and fluoroquinolone antibiotics, and imidazole/triazole antifungals.[1]

Concomitant use should be avoided or undertaken with extreme caution, including ECG monitoring, in patients with a history of cardiac disease or congenital long QT syndrome.46

Methemoglobinemia

Co-administration of Pyronaridine can increase the risk or severity of methemoglobinemia, a condition where hemoglobin is oxidized and unable to transport oxygen effectively. This interaction is particularly relevant with local anesthetics (e.g., Articaine, Benzocaine, Lidocaine, Procaine) and other drugs such as Dapsone and Capsaicin.[1]

Cytochrome P450 (CYP) Interactions

In vitro data indicate that Pyronaridine is an inhibitor of the CYP2D6 enzyme. This enzyme is responsible for the metabolism of many commonly used drugs. Co-administration of Pyronaridine could therefore increase the plasma concentrations and potential toxicity of CYP2D6 substrates. Caution is particularly warranted for drugs with a narrow therapeutic index, such as the antiarrhythmics flecainide and propafenone, and the beta-blocker metoprolol.[46] A dedicated clinical drug-drug interaction study has been conducted to formally evaluate the interaction with metoprolol.[49]

Table 4: Clinically Significant Drug-Drug Interactions with Pyronaridine

Interacting Drug / Class	Potential Clinical Effect	Management Recommendation / Comment
QTc-Prolonging Agents (e.g., certain antimalarials, antipsychotics, macrolides)	Increased risk of cardiac arrhythmia (Torsades de Pointes)	Avoid concomitant use if possible. Use with caution and consider ECG monitoring, especially in patients with pre-existing cardiac conditions.
Local Anesthetics (e.g., Lidocaine, Benzocaine, Articaine) & Dapsone	Increased risk of methemoglobinemia	Use with caution and monitor for signs of cyanosis or respiratory distress.
CYP2D6 Substrates (e.g., Metoprolol, Flecainide, Propafenone)	Increased plasma concentrations and potential toxicity of the co-administered drug	Use with caution. Monitor for adverse effects of the interacting drug; dose adjustment may be necessary.

4.4 Contraindications and Precautions

Based on the safety and pharmacology profile, specific contraindications and precautions have been established to ensure the safe use of Pyronaridine-artesunate.

Absolute Contraindications

The use of Pyramax is absolutely contraindicated in the following situations [46]:

• Known hypersensitivity to pyronaridine, artesunate, or any of the excipients in the formulation.
• Patients with severe liver disease (e.g., decompensated cirrhosis, Child-Pugh stage B or C).
• Patients presenting with clinical signs or symptoms of hepatic injury (e.g., nausea and/or abdominal pain associated with jaundice).
• Patients with severe renal impairment.

Warnings and Precautions for Use

• Malaria Prophylaxis: Pyramax is indicated for treatment only and must not be used for the prevention (prophylaxis) of malaria.[46]
• Severe Malaria: It is not indicated for the treatment of severe or complicated manifestations of malaria, such as cerebral malaria, pulmonary edema, or severe anemia. Patients with severe malaria require parenteral therapy.[46]
• Pregnancy: As per current guidelines, use is not recommended during the first trimester unless it is the only available and potentially life-saving treatment. Data supports its use in the second and third trimesters.[46]
• Lactation: It is unknown if Pyronaridine or its metabolites are excreted in human breast milk. Due to the lack of data, it is recommended that alternative methods of infant nutrition be used during the treatment period.[15]

V. Regulatory Status and Practical Application

The journey of Pyronaridine-artesunate from a development candidate to a globally recommended antimalarial has been shaped by a novel regulatory strategy designed to accelerate access in the countries most affected by malaria. Its current regulatory standing and clear, evidence-based dosing guidelines are critical for its effective deployment in public health programs.

5.1 Global Regulatory Approvals and Recommendations

The regulatory pathway for Pyramax is a successful example of leveraging the expertise of stringent regulatory authorities for global health benefit. This approach has facilitated its adoption by international health bodies and national malaria control programs.

• European Medicines Agency (EMA): In 2012, Pyramax received a positive scientific opinion from the EMA under its Article 58 procedure.[2] This unique regulatory mechanism allows the EMA, on behalf of the European Commission, to assess and provide an opinion on medicines that are intended for use exclusively in markets outside of the European Union. It is designed specifically for medicines that prevent or treat diseases of major public health interest. An Article 58 positive opinion is considered equivalent to an approval from a stringent regulatory authority and serves as a robust endorsement of a product's quality, safety, and efficacy.[27]
• World Health Organization (WHO): Following the positive EMA opinion, Pyramax was added to the WHO's list of prequalified medicines.[2] The WHO Prequalification program ensures that medicines supplied by procurement agencies like The Global Fund and UNICEF meet acceptable standards of quality, safety, and efficacy. This status is a critical prerequisite for large-scale procurement and distribution in low- and middle-income countries. Furthermore, Pyronaridine-artesunate is included in the WHO Model List of Essential Medicines for both adults and children.[8] The 2022 update to the WHO's Guidelines for the treatment of malaria now strongly recommends Pyronaridine-artesunate as a first-line treatment for uncomplicated P. falciparum and blood-stage P. vivax malaria.[7]
• U.S. Food and Drug Administration (FDA): The regulatory status in the United States differs significantly. On September 27, 2018, the fixed-dose combination of pyronaridine tetraphosphate and artesunate was granted an Orphan Drug Designation by the FDA for the treatment of malaria.[50] This designation provides incentives for the development of drugs for rare diseases. However, it is crucial to note that Pyronaridine-artesunate is not approved by the FDA for the treatment of malaria or any other indication.[50] Its development and regulatory strategy were primarily focused on global health markets where malaria is endemic, rather than the US market.
• National Approvals: Leveraging the EMA opinion and WHO Prequalification, Pyramax has been registered in numerous malaria-endemic countries. As of early 2024, the tablet formulation is approved in 28 countries and the pediatric granule formulation is approved in 19 countries, primarily across Africa and Asia, and has been incorporated into at least 11 national treatment guidelines.[27]

5.2 Dosage and Administration Guidelines

The clinical use of Pyramax is governed by a simple, weight-based dosing regimen designed to maximize efficacy and adherence while ensuring safety across a wide range of patient ages and sizes.

General Regimen

Pyramax is administered orally, once daily, for a fixed duration of three consecutive days.[3] A key practical advantage is that its absorption is not significantly affected by food, so it can be taken with or without meals.[32]

Weight-Based Dosing

Dosing is strictly determined by the patient's body weight, using one of two available formulations.

• Pyramax® Granules for oral suspension (60 mg pyronaridine tetraphosphate / 20 mg artesunate per sachet): This formulation is indicated for infants and children with a body weight from 5 kg to under 20 kg.[3]
• Pyramax® Tablets (180 mg pyronaridine tetraphosphate / 60 mg artesunate per tablet): This formulation is indicated for adults and children with a body weight of 20 kg or more.[3]

Administration Instructions

• Vomiting: If a patient vomits within 30 minutes of taking the first dose, the entire dose should be re-administered. If the repeat dose is also vomited, an alternative antimalarial therapy should be sought, as adequate absorption cannot be guaranteed.[46]
• Missed Dose: If a dose is missed, it should be taken as soon as the patient or caregiver remembers. The subsequent doses should then be taken at the usual time to complete the full three-day course of treatment.[46]

Table 5: Weight-Based Dosing Schedule for Pyramax® Tablets and Granules

Formulation	Body Weight Range (kg)	Daily Dose (Number of Sachets/Tablets)	Total 3-Day Course (Pyronaridine mg / Artesunate mg)
Granules	5 to < 8	1 sachet	180 mg / 60 mg
	8 to < 15	2 sachets	360 mg / 120 mg
	15 to < 20	3 sachets	540 mg / 180 mg
Tablets	20 to < 24	1 tablet	540 mg / 180 mg
	24 to < 45	2 tablets	1080 mg / 360 mg
	45 to < 65	3 tablets	1620 mg / 540 mg
	≥ 65	4 tablets	2160 mg / 720 mg
Data compiled from.3

VI. Conclusion and Future Perspectives

6.1 Synthesis and Concluding Remarks

Pyronaridine, as the long-acting partner drug in the fixed-dose combination Pyronaridine-artesunate (Pyramax®), has been unequivocally established as a highly effective and generally well-tolerated first-line therapy for acute, uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Its development and successful global deployment represent a significant achievement in public health pharmacology.

The drug's unique pharmacokinetic profile, most notably its long elimination half-life and high accumulation in erythrocytes, provides a sustained parasiticidal effect that is crucial for preventing recrudescence and offers a valuable period of post-treatment prophylaxis, a distinct advantage in high-transmission settings. The primary safety concern—a risk of transient, asymptomatic hepatotoxicity—has been meticulously characterized through extensive clinical trials. This risk has been shown to be manageable and is effectively mitigated through clear contraindications in the small subset of patients with pre-existing severe liver disease. Crucially, data from large-scale studies on re-treatment have confirmed that the safety and efficacy profile remains favorable upon repeated use, supporting its role in endemic regions where multiple malaria episodes are common.

Through its successful navigation of the innovative EMA Article 58 regulatory pathway and subsequent WHO Prequalification, Pyramax serves as a vital addition to the limited global armamentarium of ACTs. It provides a critical therapeutic alternative, particularly in regions where the efficacy of older combination therapies is threatened by the inexorable spread of drug resistance.

6.2 Emerging Research and Potential for Repurposing

Beyond its established role as a cornerstone of modern malaria treatment, Pyronaridine has demonstrated a surprisingly broad spectrum of biological activity in preclinical research. This has generated considerable scientific interest in its potential for drug repurposing—finding new therapeutic uses for an existing approved drug—particularly for viral diseases and cancer. This potential stems from mechanisms of action that are distinct from its primary antimalarial effect. While its activity against Plasmodium is highly specific to the inhibition of hemozoin formation, its effects on other pathogens and on cancer cells must be mediated by other means, such as its ability to inhibit topoisomerase II or to modulate host cellular pathways.

Antiviral Activity

Preclinical studies have revealed potent in vitro and in vivo activity against several viruses of major global health concern.

• SARS-CoV-2: In the context of the COVID-19 pandemic, Pyronaridine emerged as a promising candidate for repurposing. Preclinical studies demonstrated that it could inhibit SARS-CoV-2 replication in cell culture and, importantly, reduce viral load and associated lung pathology in animal models of the disease.[10] These encouraging findings prompted the initiation of Phase II/III clinical trials to formally evaluate the safety and efficacy of Pyronaridine-artesunate in patients with mild to moderate COVID-19.[27]
• Ebola Virus (EBOV): Research has also shown remarkable activity against the Ebola virus. In vitro assays confirmed its ability to inhibit EBOV replication. Subsequent studies in a lethal mouse-adapted EBOV challenge model were highly successful, showing that a single dose of Pyronaridine administered post-infection resulted in 100% survival.[53] Further analysis suggests that its protective effect may be mediated, at least in part, by modulating the host's immune and inflammatory response to the infection.[53]

Anticancer Activity

The secondary mechanism of Pyronaridine, involving DNA intercalation and the inhibition of topoisomerase II, provides a strong rationale for its investigation as a potential anticancer agent. Topoisomerase inhibitors are an established class of chemotherapy drugs. Consistent with this mechanism, in vitro studies have shown that Pyronaridine exhibits cytotoxicity against a range of human cancer cell lines, including those derived from breast, ovarian, and lung cancers.[10]

Other Antiparasitic Activity

The drug's activity is not limited to Plasmodium. Preclinical data have also indicated efficacy against other parasites, such as Echinococcus granulosus, the cestode that causes cystic echinococcosis (hydatid disease) in humans.[10]

The exploration of Pyronaridine for these diverse and unrelated conditions suggests that its biological activity may be more complex than initially understood. Its efficacy against pathogens as different as a protozoan (Plasmodium), RNA viruses (SARS-CoV-2, Ebola), and its effects on cancer cells, points towards a potential role as a modulator of fundamental host cell pathways that are exploited during disease processes. This positions Pyronaridine not merely as an antimalarial, but as a potential platform molecule for developing treatments for other challenging diseases. The fact that it is already an approved drug with a well-documented human safety profile dramatically de-risks and accelerates its potential development for these new indications, making the ongoing repurposing research a pragmatic and potentially high-impact public health strategy.

Works cited

1. Pyronaridine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 22, 2025, https://go.drugbank.com/drugs/DB12975
2. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10545508/
3. Pyramax - opinion on medicine for use outside EU | European Medicines Agency (EMA), accessed September 22, 2025, https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/pyramax
4. What is the mechanism of Pyronaridine Phosphate? - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pyronaridine-phosphate
5. What is Pyronaridine Phosphate used for? - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/article/what-is-pyronaridine-phosphate-used-for
6. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria - Oxford Academic, accessed September 22, 2025, https://academic.oup.com/jac/article-pdf/78/10/2406/51743423/dkad260.pdf
7. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed September 22, 2025, https://academic.oup.com/jac/article/78/10/2406/7252659
8. Artesunate + pyronaridine tetraphosphate - eEML - Electronic Essential Medicines List, accessed September 22, 2025, https://list.essentialmeds.org/recommendations/796
9. Pyronaridine | C29H32ClN5O2 | CID 107771 - PubChem, accessed September 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pyronaridine
10. Pyronaridine | CAS#74847-35-1 | antimalarial - MedKoo Biosciences, accessed September 22, 2025, https://www.medkoo.com/products/8209
11. 74847-35-1|Pyronaridine|BLD Pharm, accessed September 22, 2025, https://www.bldpharm.com/products/74847-35-1.html
12. Pyronaridine | 74847-35-1 - SynZeal, accessed September 22, 2025, https://www.synzeal.com/en/pyronaridine-2
13. PYRONARIDINE - precisionFDA, accessed September 22, 2025, https://precision.fda.gov/ginas/app/ui/substances/TD3P7Q3SG6
14. Environmentally Responsible and Cost-Effective Synthesis of the ..., accessed September 22, 2025, https://pubs.acs.org/doi/10.1021/acs.orglett.2c00944
15. EU Risk Management Plan for Pyronaridine Tetraphosphate ..., accessed September 22, 2025, https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/pyramax-risk-management-plan_en.pdf
16. www.drugfuture.com, accessed September 22, 2025, https://www.drugfuture.com/chemdata/pyronaridine.html#:~:text=Properties%3A%20Hygroscopic%2C%20yellow%20needles%2C,%2D236%C2%B0%20(dec).
17. Pyronaridine | Parasite inhibitor | 99.06%(HPLC) | In Stock, accessed September 22, 2025, https://www.selleckchem.com/products/pyronaridine.html
18. CAS 76748-86-2 Pyronaridine Tetraphosphate - BOC Sciences, accessed September 22, 2025, https://www.bocsci.com/product/pyronaridine-tetraphosphate-cas-76748-86-2-351041.html
19. PRODUCT INFORMATION - Cayman Chemical, accessed September 22, 2025, https://cdn.caymanchem.com/cdn/insert/16139.pdf
20. Pyronaridine tetraphosphate-SDS-MedChemExpress, accessed September 22, 2025, https://file.medchemexpress.com/batch_PDF/HY-14749A/Pyronaridine-tetraphosphate-SDS-MedChemExpress.pdf
21. Safety Data Sheet - Cayman Chemical, accessed September 22, 2025, https://cdn.caymanchem.com/cdn/msds/16139m.pdf
22. Pyronaridine - Wikipedia, accessed September 22, 2025, https://en.wikipedia.org/wiki/Pyronaridine
23. Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Eastern Cambodia | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 22, 2025, https://journals.asm.org/doi/10.1128/aac.02242-18
24. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6754981/
25. Study Details | Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT05192265?cond=Remittent%20fever&viewType=Table&rank=8
26. THE SUCCESSFUL DEVELOPMENT OF A FIXED DOSE COMBINATION OF ARTESUNATE PLUS AMODIAQUINE ANTIMALARIAL - DNDi, accessed September 22, 2025, https://dndi.org/wp-content/uploads/2014/11/DNDi_ASAQ-story_2002-2015.pdf
27. Pyronaridine- artesunate - Medicines for Malaria Venture, accessed September 22, 2025, https://www.mmv.org/mmv-pipeline-antimalarial-drugs/pyronaridine-artesunate
28. Shinpoong Pharm.co.,LTd : Pyramax, accessed September 22, 2025, https://www.shinpoong.co.kr/en/sub2/2_5.php
29. Pyronaridine: a review of its clinical pharmacology in the treatment ..., accessed September 22, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545508/
30. Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 22, 2025, https://journals.asm.org/doi/10.1128/aac.01208-24
31. Daily dosing table for Pyramax ® (pyronaridine tetraphosphate-artesunate) - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/figure/Daily-dosing-table-for-Pyramax-R-pyronaridine-tetraphosphate-artesunate_tbl1_373452417
32. Notes on the design of bioequivalence study: Artesunate / Pyronaridine, accessed September 22, 2025, https://extranet.who.int/prequal/sites/default/files/document_files/BE_Arte-Pyro_Jan2024.pdf
33. Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines, accessed September 22, 2025, https://www.mmv.org/sites/default/files/uploads/docs/press_releases/Pyramax%20press%20release%20ENG.pdf
34. Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients., accessed September 22, 2025, https://www.mmv.org/newsroom/news-resources-search/population-pharmacokinetics-pyronaridine-pediatric-malaria-patients
35. Quantification of the antimalarial drug pyronaridine in whole blood using LC–MS/MS — Increased sensitivity resulting from reduced non-specific binding, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5637160/
36. (PDF) Mass balance and metabolism of the antimalarial ..., accessed September 22, 2025, https://www.researchgate.net/publication/260485523_Mass_balance_and_metabolism_of_the_antimalarial_pyronaridine_in_healthy_volunteers
37. Pyramax® approved as antimalarial for treatment of multiple episodes of malaria - EDCTP, accessed September 22, 2025, http://www.edctp.org/news/pyramax-approved-antimalarial-treatment-multiple-episodes-malaria/
38. (PDF) Safety and efficacy of re-treatments with pyronaridine ..., accessed September 22, 2025, https://www.researchgate.net/publication/283965922_Safety_and_efficacy_of_re-treatments_with_pyronaridine-artesunate_in_African_patients_with_malaria_A_substudy_of_the_WANECAM_randomised_trial
39. Re-treating malaria with Pyramax®: WANECAM study supports safety and efficacy - EDCTP, accessed September 22, 2025, https://www.edctp.org/news/re-treating-malaria-pyramax-wanecam-study-supports-safety-efficacy/
40. (PDF) Pyronaridine–Artesunate versus Mefloquine plus Artesunate ..., accessed September 22, 2025, https://www.researchgate.net/publication/223957493_Pyronaridine-Artesunate_versus_Mefloquine_plus_Artesunate_for_Malaria
41. Study Details | NCT00403260 | Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients | ClinicalTrials.gov, accessed September 22, 2025, https://www.clinicaltrials.gov/study/NCT00403260
42. Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7470518/
43. Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6353203/
44. Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9209011/
45. Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 22, 2025, https://journals.asm.org/doi/10.1128/aac.00044-24
46. Pyramax, INN - pyronaridine tetraphosphate /artesunate, accessed September 22, 2025, https://shinpoong.co.kr/en/file/Pyramax_SmPC.pdf?v=1
47. Pyramax, INN-pyronaridine / artesunate - European Medicines Agency, accessed September 22, 2025, https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/pyramax-h-w-2319-x-0008-g-assessment-report-extension_en.pdf
48. Pyramax ® label update: Now includes information for the treatment ..., accessed September 22, 2025, https://www.mmv.org/newsroom/news-resources-search/pyramax-r-label-update-now-includes-information-treatment-pregnant
49. Pyronaridine Completed Phase 1 Trials for Malaria Treatment | DrugBank Online, accessed September 22, 2025, https://go.drugbank.com/drugs/DB12975/clinical_trials?conditions=DBCOND0007188&phase=1&purpose=treatment&status=completed
50. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed September 22, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=651218
51. Study Details | NCT04701606 | The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT04701606
52. The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients - Reagan-Udall Foundation, accessed September 22, 2025, https://reaganudall.org/clinical-trial/safety-and-efficacy-pyronaridine-artesunate-pyramaxr-or-artecomrin-covid-19-patients
53. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6894882/
54. Long-term stability of pyronaridine at −80 • C. | Download Table - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/figure/Long-term-stability-of-pyronaridine-at-80-C_tbl1_319309970